Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
PET imaging of activated microglia offers a tool of investigation of a range of brain diseases where neuroinflammation is a component.
Amyotrophic lateral sclerosis is the most frequent motoneuronal disease in adult.
This study was designed to explore the feasibility of molecular imaging modality by Positron Emission Tomography using 18F-X as an in vivo marker of activated microglia for the assessment of neuroinflammation in amyotrophic lateral sclerosis.
PET may help in the diagnosis of the disease and, further, may allow assessment of the efficacy of antiinflammatory treatment.
18F-X PET will be carried out requiring arterial sampling in 2 patients suffering from ALS and 2 normal subjects in order to evaluate the 18F-X quantification.
Then simplified PET using 18F-X will be carried out in 13 patients and 13 normal subjects.
Binding potential maps showing specific binding of 18f-X will be generated for each subject.
Regional binding potential values will be calculated for anatomically defined regions of interest after coregistration to and special transformation into the subject's own MRI.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | 18F-X PET Scan imaging |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 18F-X PET SCAN | Radiation | 18F-X PET Scan : Injection of 7.8 mSv for 370 MBq of dose (0.021 mSv / MBq) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Quantitative in vivo-imaging of 18F-X microglial binding site as a mesure of disease activity followed up by non invasive quantification of patients using imaging modality. | Inclusion period |
| Measure | Description | Time Frame |
|---|---|---|
| Evidence of the localisation of benzodiazepine binding site related to microglial activation in ALS | inclusion period | |
| Evidence of the difference of microglial localisation and activation between bulbar and spinal form of amyotrophic lateral sclerosis |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Catherine ROUSSEL | Contact | (33) 2.47.47. 97.89 | roussel@med.univ-tours.fr |
| Name | Affiliation | Role |
|---|---|---|
| Denis GUILLOTEAU, PHD | Service de médecine nucléaire in Vitro - CHRU TOURS | Study Director |
| Philippe CORCIA, MD | Service de Neurologie - CHRU Tours | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Service de Médecine Nucléaire et Ultrasons - Hôpital Bretonneau | Recruiting | Tours | Centre-Val de Loire | 37044 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 15850659 | Background | Kassiou M, Meikle SR, Banati RB. Ligands for peripheral benzodiazepine binding sites in glial cells. Brain Res Brain Res Rev. 2005 Apr;48(2):207-10. doi: 10.1016/j.brainresrev.2004.12.010. Epub 2005 Jan 22. | |
| 12379908 | Background | Banati RB. Visualising microglial activation in vivo. Glia. 2002 Nov;40(2):206-217. doi: 10.1002/glia.10144. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| inclusion period |
| 11050032 | Result | Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, Price G, Wegner F, Giovannoni G, Miller DH, Perkin GD, Smith T, Hewson AK, Bydder G, Kreutzberg GW, Jones T, Cuzner ML, Myers R. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain. 2000 Nov;123 ( Pt 11):2321-37. doi: 10.1093/brain/123.11.2321. |
| 17978354 | Result | Zhang MR, Kumata K, Maeda J, Yanamoto K, Hatori A, Okada M, Higuchi M, Obayashi S, Suhara T, Suzuki K. 11C-AC-5216: a novel PET ligand for peripheral benzodiazepine receptors in the primate brain. J Nucl Med. 2007 Nov;48(11):1853-61. doi: 10.2967/jnumed.107.043505. |
| 15084121 | Result | Zhang MR, Maeda J, Ogawa M, Noguchi J, Ito T, Yoshida Y, Okauchi T, Obayashi S, Suhara T, Suzuki K. Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for pet imaging of peripheral benzodiazepine receptor in primate brain. J Med Chem. 2004 Apr 22;47(9):2228-35. doi: 10.1021/jm0304919. |
| 23300829 | Derived | Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J, Nicolas G, Venel Y, Hommet C, Baulieu JL, Cottier JP, Roussel C, Kassiou M, Guilloteau D, Ribeiro MJ. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One. 2012;7(12):e52941. doi: 10.1371/journal.pone.0052941. Epub 2012 Dec 31. |
| ID | Term |
|---|---|
| D000690 | Amyotrophic Lateral Sclerosis |
| D013122 | Spinal Diseases |
| D012598 | Sclerosis |
| ID | Term |
|---|---|
| D013118 | Spinal Cord Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D016472 | Motor Neuron Disease |
| D019636 | Neurodegenerative Diseases |
| D057177 | TDP-43 Proteinopathies |
| D009468 | Neuromuscular Diseases |
| D057165 | Proteostasis Deficiencies |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided